 CDMO 2.0 market.JPG)
Lipid Nanoparticles (LNPs) CDMO 2.0 Market Size is predicted grow at a 16.4 % CAGR during the forecast period for 2025-2034.
-CDMO-2.0-market-info.webp "Lipid Nanoparticles (LNPs) CDMO 2.0 market info")
The Lipid Nanoparticles (LNPs) CDMO 2.0 is the next stage of contract development and manufacturing services that are specifically designed for the rapidly expanding field of advanced biologics, vaccines, and RNA therapeutics. In contrast to conventional CDMO models, this new generation emphasizes the integration of digital quality systems and AI-driven optimization with specialized lipid chemistry, scalable formulation technologies, and GMP-compliant manufacturing platforms.
LNPs CDMO 2.0 promotes end-to-end solutions, including excipient selection, nanoparticle design, analytical characterization, sterilized fill-finish, and regulatory documentation. This approach facilitates more flexible, safer, and expedited pathways for clients. The increasing demand for personalized medicine, the surge in nucleic acid-based therapeutics, and the necessity for global supply chain resilience are the driving forces behind this evolution, which has positioned CDMOs as innovation partners rather than merely service providers.
The Lipid Nanoparticles (LNPs) CDMO 2.0 market is undergoing a rapid transformation as it responds to the increasing demand for advanced drug delivery systems, particularly for RNA-based therapeutics, vaccines, and cell and gene therapies. The growing emphasis on supply chain resilience, the urgent need for scalable and GMP-compliant delivery solutions, the expanding clinical pipeline of mRNA and gene therapies, and the increasing investment from both biotech start-ups and large pharmaceutical companies are the primary drivers shaping this market.
In addition to isolated manufacturing operations, CDMOs are increasingly anticipated to provide end-to-end services, such as excipient sourcing, nanoparticle formulation, analytical validation, sterile fill-finish, and global regulatory support. In the future, the LNPs CDMO 2.0 market is expected to experience significant growth due to the increased emphasis on sustainable manufacturing practices, regionalized production to mitigate supply chain risks, and personalized medicine. This will position CDMOs as strategic innovation partners that are driving the next wave of nucleic acid therapeutics.
Some of the Major Key Players in the Lipid Nanoparticles (LNPs) CDMO 2.0 Market are
· CordenPharma
· Lonza Group AG
· Thermo Fisher Scientific (Patheon)
· Evonik Health Care (Vancouver site – formerly Transferra Nanosciences)
· WuXi Biologics / WuXi AppTec
· BIOVECTRA
· Catalent
· Samsung Biologics
· Rentschler ATMP
· Curapath
· eTheRNA Manufacturing
· Phosphorex
· NOF CORPORATION
· NeoSome Life Sciences
· Helix Biotech
· NanoImaging Services (NIS)
· Envol Biomedical
The lipid nanoparticles (LNPs) CDMO 2.0 market is segmented into product type/payload type, scale of operation, CDMO 2.0 business model, therapeutic area, end user. Based on the product type, the market is segmented into mRNA, siRNA / saRNA, plasmid DNA (pDNA), CRISPR/Cas components, microRNA, antisense oligos & other nucleic acids. Based on the scale of operation, the market is divided into preclinical, clinical (phase I–III), and commercial.
Based on the CDMO 2.0 business model, the market is divided into Tech-enabled CDMOs, niche-focused CDMOs, end-to-end integrated CDMOs, and sustainability-driven CDMOs. Based on the therapeutic area, the market is divided into infectious diseases, oncology, rare & genetic disorders, neurology & regenerative medicine. Based on the End User, the market is divided into pharmaceutical & biotech companies, academic & research institutes, government & NGOs
The active pharmaceutical ingredient (API), mRNA, is contained in LNPs, which help carry the fragile, negatively charged mRNA into target cells and shield it from RNase breakdown. By serving as a barrier, LNPs facilitate effective cellular absorption and endosomal escape for the translation of mRNA into proteins. Because of the physical characteristics of mRNA (such as its instability and negative charge), specific LNP formulations are required. The scalability of LNPs is highlighted by CDMO 2.0 suppliers, who use cutting-edge technology like microfluidics and proprietary ionizable lipids to maximize mRNA encapsulation efficiency and guarantee the quick development of mRNA COVID-19 vaccines. This results in higher CDMO investments in manufacturing capacity. The need for adaptable LNP platforms is driven by mRNA's versatility for gene treatments and customized cancer vaccinations. To help with these efforts, CDMO 2.0 vendors provide high-throughput screening and quick payload adaptation.
End-to-end integrated CDMOs offer a comprehensive range of services spanning from early-stage research through to commercial-scale manufacturing, streamlining the development and production of LNP-based therapeutics. These organizations ensure robust documentation and raw material traceability, such as high-purity lipids, while providing regulatory expertise that can shorten approval timelines by 6–8 months. By adhering to international standards, they enable cross-border market entry, which is vital for the global distribution of vaccines and advanced therapies. In addition, their capabilities extend to supporting emerging modalities like CRISPR-Cas9 and saRNA delivery, where precise LNP formulations are essential for addressing complex genetic disorders with high accuracy and therapeutic potential.
North America, particularly the United States, is home to major pharmaceutical and biotech companies and leading CDMOs specializing in LNP technologies. The region hosts world-class academic and research institutes that collaborate with industry to advance LNP formulations. These institutions pioneer technologies like microfluidic mixing and AI-driven lipid optimization, critical for CDMO 2.0 services. The interconnected network of biotechs, research centers, and CDMOs fosters rapid innovation, enabling North America to lead in developing and scaling LNP-based therapeutics, such as mRNA vaccines and gene therapies. The region’s biotech startups, focused on mRNA and LNP technologies, receive significant venture capital, further fueling CDMO demand for development and manufacturing services.
· In Jan 2025, Evonik collaborated with ST Pharm, a business that produces gene therapy active ingredients, to increase the scope of its RNA and nucleic acid therapeutic offerings. Through the collaboration, Evonik will be able to offer ST Pharm's tailored nucleic acids in addition to its range of lipid and lipid nanoparticle (LNP) therapeutic product development services. Pharmaceutical companies can accelerate the speed-to-market and decrease complexity for nucleic acid therapies by using this simplified technique. Evonik's Health Care business, which is a part of the company's Nutrition & Care division, is expanding its portfolio of system solutions for nucleic acid therapies by partnering with industry and life sciences leaders and making large investments.
· In June 2024, CordenPharma joined forces with Certest, a Spanish business that specializes in API synthesis and drug delivery using lipid nanoparticles (LNPs), to create a line of ionizable lipids for LNP formulations. CordenPharma specializes in producing injectable drug products, LNPs comprising xRNA/xDNA, and drug substances for complicated modalities, including peptides, N-acetylgalactosamine (GalNAc), and lipids, among others.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 16.4% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type / Payload Type, Scale of Operation, CDMO 2.0 Business Model, Therapeutic Area, End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
CordenPharma, Lonza Group AG, Thermo Fisher Scientific (Patheon), Evonik Health Care (Vancouver site – formerly Transferra Nanosciences), WuXi Biologics / WuXi AppTec, BIOVECTRA, Catalent, Samsung Biologics, Rentschler ATMP, Curapath, eTheRNA Manufacturing, Phosphorex, NOF CORPORATION, NeoSome Life Sciences, Helix Biotech, NanoImaging Services (NIS), Envol Biomedical |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market Snapshot
Chapter 4. Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Lipid Nanoparticles (LNPs) CDMO 2.0 Market Industry Trends
4.10. Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Lipid Nanoparticles (LNPs) CDMO 2.0 Market Segmentation 1: By Product Type / Payload Type, Estimates & Trend Analysis
5.1. Market Share by Product Type / Payload Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type / Payload Type:
5.2.1. mRNA
5.2.2. siRNA / saRNA
5.2.3. Plasmid DNA (pDNA)
5.2.4. CRISPR/Cas CDMO 2.0 Business Models
5.2.5. microRNA, Antisense Oligos & Other Nucleic Acids
Chapter 6. Lipid Nanoparticles (LNPs) CDMO 2.0 Market Segmentation 2: By Scale of Operation, Estimates & Trend Analysis
6.1. Market Share by Scale of Operation, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Scale of Operation:
6.2.1. Preclinical
6.2.2. Clinical (Phase I–III)
6.2.3. Commercial
Chapter 7. Lipid Nanoparticles (LNPs) CDMO 2.0 Market Segmentation 3: By CDMO 2.0 Business Model, Estimates & Trend Analysis
7.1. Market Share by CDMO 2.0 Business Model, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following CDMO 2.0 Business Model:
7.2.1. Tech-Enabled CDMOs
7.2.2. Niche-Focused CDMOs
7.2.3. End-to-End Integrated CDMOs
7.2.4. Sustainability-Driven CDMOs
Chapter 8. Offline Lipid Nanoparticles (LNPs) CDMO 2.0 Market Segmentation 4: By Therapeutic Area, Estimates & Trend Analysis
8.1. Market Share by Therapeutic Area, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Area:
8.2.1. Infectious Diseases
8.2.2. Oncology
8.2.3. Rare & Genetic Disorders
8.2.4. Neurology & Regenerative Medicine
Chapter 9. Lipid Nanoparticles (LNPs) CDMO 2.0 Market Segmentation 5: By End User, Estimates & Trend Analysis
9.1. Market Share by End User, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
9.2.1. Pharmaceutical & Biotech Companies
9.2.2. Academic & Research Institutes
9.2.3. Government & NGOs
Chapter 10. Lipid Nanoparticles (LNPs) CDMO 2.0 Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Product Type / Payload Type, 2021-2034
10.2.3. North America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.2.4. North America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by CDMO 2.0 Business Model, 2021-2034
10.2.5. North America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.2.6. North America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.3. Europe
10.3.1. Europe Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Product Type / Payload Type, 2021-2034
10.3.3. Europe Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.3.4. Europe Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by CDMO 2.0 Business Model, 2021-2034
10.3.5. Europe Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.3.6. Europe Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Product Type / Payload Type, 2021-2034
10.4.3. Asia Pacific Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.4.4. Asia Pacific Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts Therapeutic Area, 2021-2034
10.4.5. Asia Pacific Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.5. Latin America
10.5.1. Latin America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Product Type / Payload Type, 2021-2034
10.5.3. Latin America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.5.4. Latin America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by CDMO 2.0 Business Model, 2021-2034
10.5.5. Latin America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.5.6. Latin America Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Product Type / Payload Type, 2021-2034
10.6.3. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
10.6.4. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by CDMO 2.0 Business Model, 2021-2034
10.6.5. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.6.6. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. CordenPharma
11.2.1.1. Business Overview
11.2.1.2. Key Product Type / Payload Type/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Lonza Group AG
11.2.3. Thermo Fisher Scientific (Patheon)
11.2.4. Evonik Health Care (Vancouver site – formerly Transferra Nanosciences)
11.2.5. WuXi Biologics / WuXi AppTec
11.2.6. BIOVECTRA
11.2.7. Catalent
11.2.8. Samsung Biologics
11.2.9. Rentschler ATMP
11.2.10. Curapath
11.2.11. eTheRNA Manufacturing
11.2.12. Phosphorex
11.2.13. NOF CORPORATION
11.2.14. NeoSome Life Sciences
11.2.15. Helix Biotech
11.2.16. NanoImaging Services (NIS)
11.2.17. Envol Biomedical
Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market- By Product Type / Payload Type
· mRNA
· siRNA / saRNA
· Plasmid DNA (pDNA)
· CRISPR/Cas Components
· microRNA, Antisense Oligos & Other Nucleic Acids
-CDMO-2.0-market-segment.webp "Lipid Nanoparticles (LNPs) CDMO 2.0 market segment")
Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market – By Scale of Operation
· Preclinical
· Clinical (Phase I–III)
· Commercial
Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market – By CDMO 2.0 Business Model
· Tech-Enabled CDMOs
· Niche-Focused CDMOs
· End-to-End Integrated CDMOs
· Sustainability-Driven CDMOs
Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market- By Therapeutic Area
· Infectious Diseases
· Oncology
· Rare & Genetic Disorders
· Neurology & Regenerative Medicine
Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market – By End User
· Pharmaceutical & Biotech Companies
· Academic & Research Institutes
· Government & NGOs
Global Lipid Nanoparticles (LNPs) CDMO 2.0 Market – By Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
